Remitted depression · cognitive decline

Remitted Depression and Cognitive Decline: A Screening Trigger

Remitted depression is a screening trigger for cognitive decline: in one cohort of older adults whose depression had lifted, about one in four developed dementia within five years. That history is a reason to set a standardized cognitive baseline and follow it.

Remission ends the mood episode, not the cognitive risk. A randomized trial built to slow decline in this group shows why the history belongs on the screening list.

Remitted depression and cognitive decline travel together in older adults, and most charts stop tracking cognition the day the mood improves. The PACt-MD trial in Toronto showed that a combined prefrontal intervention could slow cognitive decline in exactly this group, with the clearest effect in patients whose depression was in remission. Measura [Cardiometabolic and Autonomic Health Analysis] provides neither the brain stimulation nor the cognitive remediation used in the trial. The primary care lesson sits upstream of both: a history of late-life depression is a reason to establish a standardized cognitive assessment baseline and follow it.

The risk that persists after remission

A 2025 umbrella review and meta-analysis pooled 18 studies of depression with onset in later life, covering 901,762 participants and 7,595 incident dementia cases, and found a hazard ratio of 1.95 for all-cause dementia; depression assessed in midlife carried a hazard ratio of 1.56. Heterogeneity was substantial, and the authors note that part of the late-life signal may be early neurodegeneration presenting as mood change. Either reading argues for measurement, the case developed in pairing cognitive screening with the metabolic picture.

Clinical cohorts show what that looks like. In a prospective study of 130 older adults with remitted major depression and 100 normal controls, 98 patients and 55 controls completed 5-year follow-up; among the patients, 28.6% had mild cognitive impairment and 25.5% developed dementia within 5 years, an approximate 3 times higher risk of subsequent cognitive decline. Slower information-processing speed and weaker memory at baseline predicted conversion. In a separate cohort of 185 adults with remitted late-life depression and 114 never-depressed controls followed an average of 5 years, the remitted group started with measurable impairment. Those whose first episode came at 60 or later performed worse across domains and declined faster in verbal skills and delayed memory. Age at first episode is a triage variable most charts never record. Stress physiology is part of that picture, and its daily timing is covered in how gut bacteria shape the stress rhythm.

What the PACt-MD trial tested

The trial ran at 5 academic hospitals in Toronto. It enrolled older adults with remitted major depression, with or without mild cognitive impairment, aged 65 and older, or mild cognitive impairment without depression, aged 60 and older. Of 486 who consented, 375 received at least one session; mean age was 72.2 years. The active arm combined cognitive remediation, structured computer-based exercises, with transcranial direct current stimulation targeting the prefrontal cortex, 5 days a week for 8 weeks, followed by twice-yearly 5-day boosters and daily at-home remediation. The comparison arm received sham versions of both. Participants were assessed yearly for 3 to 7 years, over a median follow-up of 48.3 months.

What it found, and what it did not

The active treatment slowed decline on the global cognitive composite, with an adjusted z score difference of 0.21 at month 60, and showed effects on executive function and verbal memory. It produced no meaningful acute improvement at month 2 (0.06), and its effect on progression to mild cognitive impairment or dementia was weak and not statistically significant, with a hazard ratio of 0.66. Benefit was larger in participants with remitted depression and in APOE ε4 noncarriers.

Two secondary reports from the trial refine who responds. Among 246 participants with analyzable baseline MRI, cortical thickness moderated the treatment effect on global cognition, executive function and verbal memory. Among 143 participants in the active arm, a stronger stimulation-induced electric field in the left dorsolateral prefrontal cortex was associated with slower decline.

The non-obvious result is the shape of the effect. An intervention that did nothing measurable at two months separated from sham years later. A single post-treatment score would have called it a failure. Prevention in cognition is visible only through standardized, repeated measurement, and the same is true of the decline a practice is trying to catch, which is how serial results are interpreted. The second point is where the benefit concentrated: in noncarriers of the strongest genetic risk variant, which places the modifiable portion in the terrain rather than the genotype. Protocols that demand years of sessions also favor patients well enough to attend them; the depressed older patient with diabetes, chronic pain and a long medication list is the one primary care actually holds, and the one who most needs measuring. The other changeable risks this patient carries are organized by visit in measuring modifiable dementia risk factors.

Why depression and cognition share a terrain

Two biological drivers link them. The first is prefrontal and executive network dysfunction, the circuit the trial targeted, which impairs processing speed and planning long after mood recovers. The second is systemic: an inflamed subgroup of depressed patients carries elevated inflammatory markers and insulin resistance, the same metaflammation that injures cerebral small vessels and impairs neuronal fuel supply. The third driver is social. Late-life depression clusters with bereavement, retirement, isolation and loneliness, each of which removes daily cognitive and social load. Treatment accordingly includes behavior with a physiological rationale: aerobic and resistance exercise improve insulin sensitivity and cerebral blood flow, and sustained social contact keeps the executive networks under demand. Insulin signaling inside the brain is one of those shared routes, traced in what brain tissue shows about insulin resistance.

Who to screen and what to measure

• Adults 65 and older with a documented history of major depression now in remission.
• Any patient whose first depressive episode began at 60 or later.
• Remitted depression with subjective memory or processing-speed complaints.
• Remitted depression with central adiposity, insulin resistance or vascular risk factors.

A cognitive assessment administered the same way each time provides the baseline and the serial comparison. Laboratory panels address reversible contributors to a low score, including vitamin B12 and a full thyroid panel, and the metabolic drivers, including fasting insulin and high-sensitivity C-reactive protein. Candidates for cognitive remediation or brain stimulation are referred to geriatric psychiatry or research programs; Measura’s role ends at identification and measurement.

The annual wellness visit already screens for depression and reviews cognition, which makes it the natural place to flag a remitted history. Standing orders can start the cognitive and laboratory measurements when that flag is present, and selection criteria keep the trigger consistent across clinicians. Where gait or balance is also a concern, cognitive assessment and fall prevention describes the pairing.

Frequently asked questions

References

• Rajji, T. K., Bowie, C. R., Herrmann, N., Pollock, B. G., Lanctôt, K. L., Kumar, S., et al., & PACt-MD Study Group. (2025). Slowing Cognitive Decline in Major Depressive Disorder and Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA Psychiatry, 82(1), 12-21. https://doi.org/10.1001/jamapsychiatry.2024.3241
• Brain, J., Alshahrani, M., Kafadar, A. H., Tang, E. Y., Burton, E., Greene, L., et al., & Stephan, B. C. (2025). Temporal dynamics in the association between depression and dementia: an umbrella review and meta-analysis. eClinicalMedicine, 84, 103266. https://doi.org/10.1016/j.eclinm.2025.103266
• Lin, Y. J., Huang, M. F., Yeh, Y. C., & Chen, C. S. (2024). Predicting risk of dementia among the elderly with major depressive disorder in remission: A prospective study. International Journal of Geriatric Psychiatry, 39(2), e6065. https://doi.org/10.1002/gps.6065
• Ly, M., Karim, H. T., Becker, J. T., Lopez, O. L., Anderson, S. J., Aizenstein, H. J., et al., & Butters, M. A. (2021). Late-life depression and increased risk of dementia: a longitudinal cohort study. Translational Psychiatry, 11(1), 147. https://doi.org/10.1038/s41398-021-01269-y
• Ho, N. C. W., Zhukovsky, P., Rajji, T. K., Bowie, C. R., Brooks, H., Butters, M. A., et al., & PACt-MD Study Group. (2026). Brain Structures and Cognitive Decline: Moderation Analysis of the PACt-MD Randomized Clinical Trial of Brain Stimulation Plus Cognitive Remediation in Older Adults With Remitted Depression or Mild Cognitive Impairment. The American Journal of Geriatric Psychiatry, 34(8), 1005-1015. https://doi.org/10.1016/j.jagp.2026.04.008
• Mirjalili, M., Brooks, H., Ma, C., Lee, A., Bikson, M., Voineskos, A. N., et al., & PACt-MD Study Group. (2025). Impact of Transcranial Direct Current Stimulation-Induced Electric Fields on Slowing Cognitive Decline in Older Adults With Mild Cognitive Impairment or Remitted Major Depressive Disorder: An Analysis of the PACt-MD Randomized Clinical Trial. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2025.09.020

Related reading

• Inflammation and Depression: Identifying the Inflamed Subgroup
• Cognitive Screening in Primary Care: Add the Metabolic Picture
• Cognitive Assessment

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.